Moleculin Biotech, Inc.
MBRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001659617
In the last 90 days, Moleculin Biotech, Inc. insiders filed 3 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $518.5K in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 3
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −2 vs. previous quarter
- 18
- 13F valueReported value at the end of Q2 2026
- $518.5K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding MBRX, Q2 2026
No superinvestor reported holding MBRX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Moleculin Biotech, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 5, 2026 (view filing)4:16 PM ET | Aug 3 | 2 days | Foster Jonathan P.Chief Financial Officer | PPurchase | +293.3K | – | – | +2,377.1%305.7K after | |
| Aug 5, 2026 (view filing)4:16 PM ET | Aug 3 | 2 days | Foster Jonathan P.Chief Financial Officer | PPurchase | +880.0K | – | – | –1.03M after | Derivative |
| Aug 5, 2026 (view filing)4:16 PM ET | Aug 3 | 2 days | Klemp Walter VCEO and President | PPurchase | +533.3K | – | – | +1,720.0%564.3K after | |
| Aug 5, 2026 (view filing)4:15 PM ET | Aug 3 | 2 days | Picker Donald HChief Science Officer | PPurchase | +173.3K | – | – | +23,019.0%174.1K after | |
| Aug 5, 2026 (view filing)4:15 PM ET | Aug 3 | 2 days | Picker Donald HChief Science Officer | PPurchase | +520.0K | – | – | –539.6K after | Derivative |
| Jun 23, 2025 (view filing)4:35 PM ET | Jun 23 | Same day | Foster Jonathan P.Chief Financial Officer | PPurchase | +270.3K | $0.37 | +$100.0K | +1,560.7%287.6K after | |
| Jun 23, 2025 (view filing)4:35 PM ET | Jun 23 | Same day | Foster Jonathan P.Chief Financial Officer | PPurchase | −810.8K | – | – | –1.04M after | Derivative |
| Jun 23, 2025 (view filing)4:35 PM ET | Jun 23 | Same day | Klemp Walter VCEO and President | PPurchase | +675.7K | $0.37 | +$250.0K | +994.6%743.6K after | |
| Jun 23, 2025 (view filing)4:35 PM ET | Jun 23 | Same day | Klemp Walter VCEO and President | PPurchase | −2.03M | – | – | –2.41M after | Derivative |
| Dec 27, 2023 (view filing) | Dec 26 | 1 day | Foster Jonathan P.Chief Financial Officer | PPurchase | +29.0K | $0.69 | +$20.0K | +56.2%80.6K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Moleculin Biotech, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 47,252 | $131.8K | 0.00% | +14,923+46.2% | Added |
| Vanguard Capital Management LLC | 42,215 | $117.8K | 0.00% | +28,346+204.4% | Added |
| Vanguard Fiduciary Trust Co | 29,883 | $83.4K | 0.00% | +23,811+392.1% | Added |
| XTX Topco Ltd | 22,942 | $64.0K | 0.00% | +22,942 | New |
| Morgan Stanley | 20,036 | $55.9K | 0.00% | +20,000+55,555.6% | Added |
| Rockefeller Capital Management L.P. | 15,000 | $41.9K | 0.00% | +10,579+239.3% | Added |
| Tower Research Capital LLC (TRC) | 3,514 | $9.80K | 0.00% | +1,679+91.5% | Added |
| Citigroup Inc | 2,674 | $7.46K | 0.00% | +2,674 | New |
| Barclays PLC | 621 | $1.73K | 0.00% | +621 | New |
| BlackRock, Inc. | 491 | $1.37K | 0.00% | 00.0% | Unchanged |